Combined Use of Glucagon and Milrinone May Not Be Preferable for Severe Propranolol Poisoning in the Canine Model

References

• Parmley WW. The role of glucagon in cardiac therapy. N Engl J Med 1971; 285: 801–802
   PubMed Web of Science ®Google Scholar
• Illingworth RN. Glucagon for beta-blocker poisoning. Practitioner 1979; 223: 683–685
   PubMedGoogle Scholar
• Kosinski E J, Malindzak G S, Jr. Glucagon and isoproterenol in reversing propranolol toxicity. Arch Intern Med 1973; 132: 840–843
   PubMed Web of Science ®Google Scholar
• Robson RH. Glucagon for beta-blocker poisoning. Lancet 1980; 1: 1357–1358
   PubMed Web of Science ®Google Scholar
• Ward D E, Jones B. Glucagon and beta-blocker toxicity. Br Med J 1976; 2: 151
   PubMed Web of Science ®Google Scholar
• Love J N, Leasure J A, Mundt D J, Janz TG. A comparison of amrinone and glucagon therapy for cardiovascular depression associated with propranolol toxicity in a canine model. J Toxicol Clin Toxicol 1992; 30: 399–412
   PubMed Web of Science ®Google Scholar
• Anderson J L, Baim D S, Fein S A, Goldstein R A, LeJemtel T H, Likoff MJ. Efficacy and safety of sustained (48 hr) intravenous infusions of milrinone in patients with severe congestive heart failure; a multicenter study. J Am Coll Cardiol 1987; 9: 711–722
   PubMed Web of Science ®Google Scholar
• Sato S, Tsuj M H, Okubo N, Naito H. Milrinone versus glucagon: comparative hemodynamics effects in canine propranolol poisoning. J Toxicol Clin Toxicol 1994; 32: 277–289
   PubMed Web of Science ®Google Scholar
• Critchley J A, Under A. The management of acute poisoning due to beta-adrenoceptor antagonists. Med Toxicol 1989; 4: 32–45
   Google Scholar
• Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med 1984; 13: 1123–1131
   PubMed Web of Science ®Google Scholar
• Tynan R F, Fisher M M, Ibels LS. Self-poisoning with propranolol. Med J Aust 1981; 1: 82–83
   PubMed Web of Science ®Google Scholar
• Shore E T, Cepin D, Davison MJ. Metoprolol overdose. Ann Emerg Med 1981; 10: 524–527
   PubMed Web of Science ®Google Scholar
• Glick G, Parmley W W, Wechsler A S, Sonnenblick EH. Glucagon. Its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta-receptor blockade with propranolol. Circ Res 1986; 22: 789–799
   Google Scholar
• Lucchesi BR. Cardiac actions of glucagon. Cirs Res 1968; 22: 777–787
   PubMed Web of Science ®Google Scholar
• Jacobsen D, Helgeland A, Koss A. Treatment of beta-blocker poisoning. Lancet 1980; 1: 1031–1032
   PubMedGoogle Scholar
• Sheetz M J, Tager HS. Receptor-linked proteolysis of membrane-bound glucagon yields a membrane-associated hormone fragment. j Biol Chem 1988; 263: 8509–8514
   PubMed Web of Science ®Google Scholar
• Goodman A Gliman, Rail T W, Nies A S, Taylor P. The Pharmacological Basis of Therapeutics. Pergamon Press, New York 1990
   Google Scholar
• Endoh M, Yamashita S, Taira N. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. J Pharmacol Exp. Ther 1982; 221: 775–783
   PubMed Web of Science ®Google Scholar
• Kariya T., Wille L J, Dage RC. Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043. J Cardiovasc Pharmacol 1982; 4: 509–514
   PubMed Web of Science ®Google Scholar
• Hayes J S, Bowling N, Boder G B, Kauffman R. Molecular basis for the cardiovascular activities of amrinone and AR-L57. J Pharmacol Exp Ther 1984; 230: 124–132
   PubMed Web of Science ®Google Scholar
• Bristol J A, Sircar I, Moos W H, Evans D B, Weishaar RE. Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(IH-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. J Med Chem 1984; 27: 1099–1101
   PubMed Web of Science ®Google Scholar
• Baim D S, McDowell A V, Cherniles J. Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure. N Engl J Med 1983; 309: 748–756
   PubMed Web of Science ®Google Scholar
• Maskin C S, Sinoway L, Chadwick B, Sonnenblick E H, LeJemtel TH. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Circulation 1983; 67: 1065–1070
   PubMed Web of Science ®Google Scholar
• Jaski B E, Fifer M A, Wright R F, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 1985; 75: 643–649
   PubMed Web of Science ®Google Scholar
• Monrad E S, Baim D S, Smith H S, Lanoue AS. Milrinone, dobutamine and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 1986; 73S: 168–174
   Google Scholar